A study published in Nature estimates the economic burden associated with obesity on major US industries to be in excess of $347bn in 2023.
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...
In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...
As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity ...
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start ...
The purchase price of the facility was not disclosed, but Lilly says its new $3 billion investment – part of $23 billion ...
Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed ...